In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
News|Articles|October 8, 2026
Breast Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2026
Author(s)OncLive Staff
Fact checked by: Ashling Wahner
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Advertisement
Advertisement
September brought 2 FDA approvals for ESR1-mutated advanced breast cancer, a phase 3 trial readout that missed its primary end point, new regulatory milestones for antibody-drug conjugates (ADCs) abroad, and expert perspectives on HER2-positive disease, breast cancer screening, and artificial intelligence (AI).
Related to this article
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.
The sNDA for elinzanetant seeks FDA approval for moderate to severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
Advertisement
Advertisement